GNI Group Ltd.
Notice Regarding the Disclosure of Consolidated Earnings Guidance for the Fiscal Year Ending December 2026
The consolidated revenue forecast for the fiscal year ending December 2026 is 27.158 billion yen, expected to increase approximately 1.2% compared to the previous fiscal year, while profit items remain undisclosed due to significant uncertainties.
Key Figures
- Revenue Forecast: 27,158 million yen (Fiscal Year Ending December 2026)
- Previous Fiscal Year Revenue: 26,840 million yen (Fiscal Year Ending December 2025)
- Exchange Rates: USD/JPY=155.0, CNY/JPY=21.0 (As of March 31, 2026)
AI要約
Summary of Earnings Guidance
GNI Group, Inc. disclosed the consolidated revenue forecast for the fiscal year ending December 2026 as 27.158 billion yen, which was previously undecided. This represents an approximate 1.2% increase from the previous fiscal year’s revenue of 26.840 billion yen. However, profit-related items such as operating income and beyond remain undisclosed due to multiple uncertainties including the progress of R&D expenses, timing of regulatory approvals, upfront investments related to new drug approvals, strategic investments in the medtech business, and accounting factors associated with M&A.
Outlook and Policy
Having experienced downward revisions of earnings guidance in the past two periods due to delays in regulatory approvals, the company aims to avoid causing investor confusion by excluding uncertain estimates based on regulatory approvals and will continue to withhold disclosure of profit items until a reasonable calculation is possible. The company plans to carefully monitor business trends and promptly disclose rational earnings guidance including profit items once feasible.
